A Phase IIa, known-treatment without placebo, Multicenter Study of Single-Agent MOR00208, an Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

Update Il y a 4 ans
Reference: EUCTR2012-002659-41

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To assess the antitumor activity of single-agent MOR00208 in adult patients with relapsed or refractory NHL who have received at least one prior therapy containing rituximab as one of the treatments.


Inclusion criteria

  • Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma